| 纯度 | >90%SDS-PAGE. |
| 种属 | Human |
| 靶点 | KLF7 |
| Uniprot No | O75840 |
| 内毒素 | < 0.01EU/μg |
| 表达宿主 | E.coli |
| 表达区间 | 1-302aa |
| 活性数据 | MDVLASYSIF QELQLVHDTG YFSALPSLEE TWQQTCLELE RYLQTEPRRI SETFGEDLDC FLHASPPPCI EESFRRLDPL LLPVEAAICE KSSAVDILLS RDKLLSETCL SLQPASSSLD SYTAVNQAQL NAVTSLTPPS SPELSRHLVK TSQTLSAVDG TVTLKLVAKK AALSSVKVGG VATAAAAVTA AGAVKSGQSD SDQGGLGAEA CPENKKRVHR CQFNGCRKVY TKSSHLKAHQ RTHTGEKPYK CSWEGCEWRF ARSDELTRHY RKHTGAKPFK CNHCDRCFSR SDHLALHMKR HI |
| 分子量 | 33.3 kDa |
| 蛋白标签 | GST-tag at N-terminal |
| 缓冲液 | 0 |
| 稳定性 & 储存条件 | Lyophilized protein should be stored at ≤ -20°C, stable for one year after receipt. Reconstituted protein solution can be stored at 2-8°C for 2-7 days. Aliquots of reconstituted samples are stable at ≤ -20°C for 3 months. |
| 复溶 | Always centrifuge tubes before opening.Do not mix by vortex or pipetting. It is not recommended to reconstitute to a concentration less than 100μg/ml. Dissolve the lyophilized protein in distilled water. Please aliquot the reconstituted solution to minimize freeze-thaw cycles. |
以下是关于重组人KLF7蛋白的示例性参考文献，供参考。实际文献建议通过学术数据库(如PubMed、Google Scholar)进一步验证：
---
1. **文献名称**: *"Recombinant Human KLF7 Protein Enhances Axonal Regeneration in Peripheral Nerve Injury Models"*
**作者**: Zhang L, et al.
**摘要**: 研究重组人KLF7蛋白在大鼠坐骨神经损伤模型中的作用，发现其通过激活神经再生相关基因(如GAP-43)促进轴突再生，提示其在神经修复中的潜在应用。
2. **文献名称**: *"Expression and Purification of Functional KLF7 in Escherichia coli for Transcriptional Regulation Studies"*
**作者**: Wang Y, et al.
**摘要**: 描述利用大肠杆菌系统高效表达和纯化重组人KLF7蛋白的方法，并验证其体外结合DNA启动子区域的能力，为后续功能研究提供技术基础。
3. **文献名称**: *"KLF7 Modulates Adipocyte Differentiation via BMP Signaling Pathway"*
**作者**: Tanaka K, et al.
**摘要**: 通过重组KLF7蛋白处理3T3-L1前脂肪细胞，证明其抑制脂肪生成相关基因(如PPARγ)表达，揭示KLF7在代谢疾病中的调控机制。
4. **文献名称**: *"KLF7 Exacerbates Diabetic Retinopathy by Regulating VEGF Expression"*
**作者**: Chen H, et al.
**摘要**: 在糖尿病小鼠模型中注射重组KLF7蛋白，发现其通过上调VEGF加重视网膜血管渗漏，提示KLF7作为糖尿病并发症的治疗靶点。
---
**注意**：以上文献信息为示例，实际引用需查询真实发表文章。研究重点包括重组KLF7的制备、神经修复、代谢调控及疾病机制等方向。
Recombinant human KLF7 (Krüppel-like factor 7) protein is a transcription factor engineered for research and therapeutic applications. KLF7 belongs to the Krüppel-like family of zinc-finger DNA-binding proteins, which regulate gene expression by binding to GC-rich promoter regions, notably the CACCC box. It plays critical roles in cellular processes, including differentiation, proliferation, apoptosis, and metabolism. KLF7 is particularly associated with neural development, axonal regeneration, and adipogenesis, while its dysregulation has been implicated in metabolic disorders, neurodegenerative diseases, and cancers. For instance, elevated KLF7 expression correlates with poor prognosis in glioblastoma and breast cancer, whereas its deficiency may contribute to insulin resistance in type 2 diabetes.
The recombinant form is typically produced using bacterial or mammalian expression systems, ensuring post-translational modifications that mimic native protein functionality. Purified KLF7 protein enables studies on its molecular mechanisms, such as interactions with co-regulators (e.g., p300/CBP) or genome-wide binding site mapping via ChIP-seq. Its applications extend to drug screening, gene therapy vectors, and mechanistic studies of tissue regeneration. Challenges persist in understanding its context-dependent roles due to functional redundancy within the KLF family and tissue-specific regulatory networks. Current research focuses on exploiting KLF7’s therapeutic potential by modulating its activity in neuroprotection or metabolic regulation, positioning it as a promising target for precision medicine.
×
